TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Successful Capture of IO-CEUS Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 RNA Detection in Nasal Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Urine incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of antibiotic-associated diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Mineral Density (BMD) at the Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to pulse therapy response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the therapy (% completing treatment)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flank Tissue Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestine Tissue Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Tissue Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-compliance in taking oral drug regimens
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects who develop titers of ≥ 1:40 as determined by PRNT80
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall incidence of upper GI bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in body weight following the dietary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in height following the dietary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in blood protein levels following dietary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in blood biochemistries following dietary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of AP214
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AP214
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of subject recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of delivery of the CHD intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of measuring study outcomes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvements in left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetics of AZD8931
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCD symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee society Knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Evoke Compound Action Potentials (ECAPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Drinks in a typical week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest number of drinks on one occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in baseline of DPV and LNG concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in baseline of DPV and LNG concentrations in cervicovaginal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in baseline of DPV concentration in cervical tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from parent-study baseline medial joint space width (mJSW) in the target knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Month 4 Subject Diary Composite Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced gingival inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in chronic pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of relapse of alcohol dependence
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of infants with optimally positioned endotracheal tube tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual analog scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC(0-144h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Migraine Episodes Per 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Chemical pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Completion rate of preoperative FLOT regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Collateral circulation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Types and incidence of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: parent distress/stress via Brief Symptom Inventory (BSI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: actigraph sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: actigraph sleep efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of SDB prevalence after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Graduation from juvenile drug court
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in delinquency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of PIMs Prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of preventable damages associated with medical care
Endpoint domain: Adverse events/effects
Primary endpoint: Histopathological changes according to the Modified Marsh criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of coeliac disease specific antibodies (EMA, tTGA, gliadin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of celiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined incidence of cardiovascular death or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: [18F]FDG PET/MRI as a spatial biomarker for chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Assessment of Tobacco Use Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fungal-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Highest dose of IV irinotecan without severe side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Transfusion Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune effectors in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune effectors in the marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune effectors in tumor diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correct transmission of data and anomaly events
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration (AUC (0-tn))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Hepatocellular carcinoma recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain and functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Endothelial dysfunction marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycosylated Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BOLD response during ethanol infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety measured through local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy measured by antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in expression of CD31
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CO diffusion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of Pseudomonas aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dialytic Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in patient numbers requiring secondary care appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetics (PK) and pharmacodynamics (PD) profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early bone biomarker information
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of upper gum exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Early toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience Ovarian Hyperstimulation Syndrome (OHSS)
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent rectal prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correct histological diagnosis of the mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Germline Mutation Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed growth of melanoma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Systemic indoleamine 2, 3 dioxygenase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum KYN levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varenicline area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Symptomatic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep ratings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Facial Angiofibroma Severity Index (FASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Impairment (Change From Baseline to Posttreatment) in Cohort 1: Stimulant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Impairment (Change From Baseline to Posttreatment) in Cohort 2: Non-Stimulant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain tau burden as measured by [18F]PI-2620 - PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain tau burden as measured by [18F]GTP1 - PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain tau burden as measured by [18F]MK-6240 - PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in m-Psoriasis Area Severity Index Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Abstinent time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change from baseline in meeting physical activity recommendation at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline in physical activity recommendation at 7 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline in meeting screen time recommendation at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline in meeting screen time recommendation at 7 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum diameter of abdominal aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hip Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extent of Bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hs-CRP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Performance (Specificity and Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaporometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorophotometery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meibomian gland expression and lipid analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous Preterm delivery <34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: ADHDRS-IV Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygenator blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of lung cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of lung cancer risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in plasma cobalamins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma methylmalonic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma holotranscobalamin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of solicited local adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of solicited systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Lead screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI percentile identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental fluoride varnish application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M-Entropy measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution measured in SUV values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ pharmacokinetics (PK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intratesticular Testosterone (IT-T) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intratesticular Dihydrotestosterone (DHT) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intratesticular Androstenedione (ADD) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory Test Results Meeting the Criteria for Abnormal, Grades 1-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ability to recruit, retain, and collect complete data from all participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention uptake and adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant satisfaction and acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Osteoarthritis severity as measured by PGART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoarthritis severity as measured by WOMAC VA 3.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate concentration in the left hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Classification of Roussouly type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Subject's weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subject's height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accommodative Amplitude (AA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISO-defined Cumulative and Persistent Adverse Events for Posterior Chamber IOL
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Screening in Selective Reminding Test - Consistent Long Term Retrieval (SRT-CLTR) Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Screening in Spatial Recall Test (SPART) Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Screening in Symbol Digit Modalities Test (SDMT) Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: decrease in hypernasality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects with at Least 75% Improvement in Hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroprotection/seroconversion/vaccine-response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MBF change during mental stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Follow-up imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in quantity of Bisphenol A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Information processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Inhibitory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of over-hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with ORS failure/requirement of unscheduled IV therapy
Endpoint domain: Adverse events/effects